Latest News & Updates

Latest Articles
Cabozantinib Active in Neuroendocrine Tumors
In a single-arm phase II study, cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors.
PUBLISHED: January 21, 2017
Ramucirumab Beneficial in Advanced Gastric/GEJ Cancers Regardless of Age
Patients in all age groups derived a survival benefit from treatment of advanced gastric or gastroesophageal juncture cancer with the monoclonal antibody ramucirumab, an analysis of 2 randomized trials showed.
PUBLISHED: January 21, 2017
Progression Type in HCC Influences Survival Duration
Patients with advanced hepatocellular carcinoma had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression, supporting the concept of post-progression survival and the influence of different patterns of progression, according to an analysis of the phase III RESORCE trial.
PUBLISHED: January 21, 2017
Frontline Immunotherapy Combo Setbacks Strike NSCLC
Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.
PUBLISHED: January 20, 2017
Trastuzumab Beyond Progression Shows Promise in HER2+ Gastric Cancers
Results from a retrospective multicenter study suggest that continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.
PUBLISHED: January 20, 2017
Latest Peer Exchange Discussions
MDS: The Current Understanding in Molecular Testing and Biomarkers
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
ALK-Positive Lung Cancer
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update From Orlando: Advances in Myeloproliferative NeoplasmsJan 29, 20172.0
Cancer Summaries and Commentaries™: Update from Orlando: Advances in Non-Hodgkin LymphomaJan 29, 20171.5
13th Annual School of Breast Oncology® OnlineJan 29, 201724.25
Medical Crossfire®: Mutational Testing Through Multiple Lines of NSCLC TherapyJan 29, 20171.5
Publication Bottom Border
Border Publication